• Dilshad Ahmad Khan
  • Fatima -Tuz- Zuhra
  • Farooq Ahmad Khan
  • Azhar Mubarak


Background: Several non-invasive markers are being used to assess the structural liver damage inpatients with chronic hepatitis C (CHC). We evaluated Aspartate aminotransferase (AST) toplatelet ratio index (APRI) in comparison with Metavir scoring for assessing the severity ofhepatic fibrosis in the CHC patients in district Rawalpindi. Methods: One hundred twenty CHCpatients, naive for HCV treatment, underwent liver biopsy in tertiary care hospitals of districtRawalpindi, participated in the study. Liver biopsies were reviewed by Metavir scoring system.Serum AST was analyzed by IFCC method. Platelets were measured on a haematology Analyzer.Patients with mild fibrosis (F0, F1) were differentiated from significant fibrosis (F2, F3, F4) andthose with mild/moderate fibrosis (F0, F1, F2) from advanced fibrosis (F3, F4) based on APRIscore as compared to liver biopsy. Results: Liver biopsies examination revealed that out of 120patients 10 (8.3%) had no fibrosis (F0), 46 (38%) portal fibrosis (F1), 34 (28%) septal fibrosis(F2), 21 (18%) bridging fibrosis (F3) and 9 (8%) cirrhosis (F4). APRI correctly classified 58(48%) patients of significant fibrosis with AUC=0.82 (95% CI, 0.73–0.88) at cut-off 0.5 and 1.5with negative predictive value (NPV), Positive predictive value (PPV), sensitivity and specificityof 78%, 72%, 66%, 83% and 58%, 90%, 41% and 90% respectively. Eighty-seven (66%) CHCpatients were correctly classified for advanced fibrosis with AUC=0.87(95%CI 0.79-0.94) at cutoffs 0.90 and 1.75 with a 95%NPV at 0.90 and 78% PPV at 1.75. Conclusion: APRI couldcorrectly identify significant fibrosis in 48% and advanced fibrosis in 66% cases with acceptabledegree of diagnostic accuracy in CHC patients in our clinical practice.Keywords: Chronic hepatitis C, APRI, liver biopsy, Metavir score, AST, diagnostic accuracy


Report of a WHO consultation organization in collaboration

with the viral hepatitis prevention board, Antwerp, Belgium.

Global surveillance and control of hepatitis C J Viral Hepat


Khokhar N, Gill ML, Malik GJ. General Seroprevalence of

hepatitis C and hepatitis B virus infections in population. J

Coll Physicians Surg Pak 2004;14(9):534–6.

Chen, SL, Morgan, TR. The natural history of hepatitis C

virus (HCV) infection. Int J Med Sci 2006;3(2):47–52.

J Ayub Med Coll Abbottabad 2008;20(4)


Booth JC, Grady, O’J. and Neuberger J. Clinical guidelines

on the management of hepatitis C. Gut 2001;49:1–21.

National Institutes of Health Consensus Development

Conference Statement: Management of hepatitis C: 2002,

Hepatology 2002;36:S3–S20

Bedossa P, Darge`re D, Paradis V. Sampling variability of

liver fibrosis in chronic hepatitis C. Hepatology


Poynard T, Halfon P, Castera L, Charlotte F, Bail BL,

Munteanu, M, et al. The Fibropaca group. Variability of the

area under the receiver operating characteristic curves in the

diagnostic evaluation of liver fibrosis markers: impact of

biopsy length and fragmentation. Aliment. Pharmacol. Ther


Thampanitchawong P, Piratvisuth, T. Liver biopsy

complications and risk factors. World J Gastroenterol


Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of

liver fibrosis clinical translation of molecular pathogenesis or

based on liver-dependent malfunction tests. Clinica Chimica

Acta 2007;381(2):107–13.

Adams LA, Bulsara M, Rossi E, De Boer B, Speers D,

George J, et al. Hepascore: an accurate validated predictor of

liver fibrosis in chronic hepatitis C infection. Clin. Chem


Grigoresco M, Rusu M, Necoloiu D, Radu C, Serban A,

Catanas M, et al. The FibroTest value in discriminating

between insignificant and significant fibrosis in chronic

hepatitis C patients. The Romanian experience. J

Gastrointestin Liver Dis 2007;16(1):31–7.

Reedy DW, Loo AT, Levine RA. AST/ALT ratio >or=1 is

not diagnostic of cirrhosis in patients with chronic hepatitis

C. Dig Dis Sci 1998;43:2156–9.

Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero

JA, Conjeevaram HS, et al. A simple noninvasive index can

predict both significant fibrosis and cirrhosis in patients with

chronic hepatitis C. Hepatology 2003;38:518–26.

Bergmeyer HU Herder M, Rej R. Approved recommendation

on IFCC methods for the measurement of catalytic

concentration of enzymes Part 3. (IFCC Method for Alanine

aminotransferase. J Clin Chem Clin Biochem 1998;24:481–9.

Bergmeyer HU, Herder M, Rej R. Approved

recommendation 1985 on IFCC methods for the

measurement of catalytic concentration of enzymes Part 2.

IFCC Method for asparate aminotransferase. J Clin Chem

Clin Biochem 1998;24:49.

Expert Panel on enzymes: I, IFCC methods for the

measurement of catalytic concentration of enzymes V: IFCC

method for alkaline phosphatase. Clin Chin Acta


Perry BW, Doumas BT, Bayse DD. A candidate reference

method for determination of bilirubin in serum: Test for

transferability. Clin Chem 1983;29:297–301.

The French METAVIR Cooperative Study Group,

Intraobserver and interobserver variations in liver biopsy

interpretation in patients with chronic hepatitis C.

Hepatology 1994;20:15–20.

Poynard T, Morra R, Halfon P, Castera L, Ratziu V, ImbertBismut F, et al. Meta-analyses of Fibrotest diagnostic value

in chronic liver disease. B.M.C. Gastroenterol 2007;15(7):40.

Aster R. Pooling of platelets in the spleen: role in the

pathogenesis of "hypersplenic" thrombocytopenia. J Clin

Invest. 1996;45:645–57.

George J.N. Platelets. Lancet 2000;355:1531–9.

Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili

R, Cesaro G, et al. Hepatic fibrosis plays a central role in the

pathogenesis of thrombocytopenia in patients with chronic

viral hepatitis. Br J Haematol 2001;113:590–5.

Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon

SM, et al. Mitochondrial injury, oxidative stress, and

antioxidant gene expression are induced by hepatitis C virus

core protein. Gastroenterology 2002;122:366–75.

Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma

clearance of intravenously injected aspartate

aminotransferase isozymes: evidence for preferential uptake

by sinusoidal liver cells. Hepatology 1985;5:367–75.

Silva Junior RG, Fakhouri R, Nascimento TV, Santos IM,

Barbosa LM. Aspartate aminotransferase-to-platelet ratio

index for fibrosis and cirrhosis prediction in chronic hepatitis

C patients. Braz J Infect Dis 2008;12(1):15–9.

Bourliere M, Penaranda G, Ouzan D, Renou C, BottaFridlund D, Tran A, et al. Optimized stepwise combination

algorithms of non-invasive liver fibrosis scores including

Hepascore in hepatitis C virus patients. Aliment Pharmacol

Ther 2008;28(4):458–67.

Calès P, de Ledinghen V, Halfon P, Bacq Y, Leroy V,

Boursier J. Evaluating the accuracy and increasing the

reliable diagnosis rate of blood tests for liver fibrosis in

chronic hepatitis C. Liver Int. 2008. DOI: 10.1111/j.1478-


Halfon P, Bacq Y, Muret A, Penaranda G, Bourliere M,

Ouzan D, et al. Comparison of test performance profile for

blood tests. J Hepatol 2007;46:395–402.

Bourliere M, Penaranda G, Renou C, Botta-F D, Tran A,

Portal I, et al. Validation and comparison of indexes for

fibrosis and cirrhosis prediction in chronic hepatitis C

patients: proposal for a pragmatic approach classification

without liver biopsies. J Viral Hepat 2006;13:659–70.

Trang T, Petersen JR, Snyder N. Non-invasive markers of

hepatic fibrosis in patients co-infected with HCV and HIV:

Comparison of the APRI and FIB-4 index. Clin Chim Acta


Snyder N, Gajula L and Xiao SY., Grady J, Luxon B, Lau

DT et al. APRI: An easy and validated predictor of hepatic

fibrosis in chronic hepatitis C, J Clin Gastroenterol


Snyder N, Nguyen A, Gajula L, Soloway R, Xiao SY , Lau

DT, et al. The APRI may be enhanced by the use of the

FIBROSpect II in the estimation of fibrosis in chronic

hepatitis C, Clin Chem Acta 2007;381(20):119–23.

Sebastiani G, Vario A, Guido M, Noventa F, Plebani M,

Pistis R, et al.Stepwise combination algorithms of noninvasive markers to diagnose significant fibrosis in chronic

hepatitis J Hepatol 2006;44(4):686–93.

Ramos Paesa C, Marcilla F, López G, Hueso E, Pascual A,

Aguirre JM. Evaluation of APRI and Forns models for noninvasive diagnosis of fibrosis in patients with hepatitis C in

coinfected and non-coinfected with HIV, An Med Interna




Most read articles by the same author(s)